X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Stakeholders raise concerns about ICER’s evidence report for non-small cell lung cancer

By Lauren Neves  |    October 20, 2016
The value of recent advances in non-small cell lung cancer (NSCLC) is undeniable. NSCLC is a devastating illness – 17.7 percent of lung cancer patients survive only five years following their...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the...   Read More

Who gets a seat at ICER’s table? Hint: It’s not patients

By Holly Campbell  |    September 19, 2016
As we continue the move toward a value-driven health care system, efforts to develop tools supporting patient decision-making will play a central role. These tools, including emerging value...   Read More

New PhRMA report: New medicines in development for autoimmune diseases offer patients hope for brighter futures

By Hannah Mooney  |    September 12, 2016
Currently, more than 23.5 million Americans are affected by one of the more than 80 autoimmune diseases identified to date. These diseases range in severity, with their own characteristics and...   Read More

Patients showcase longer, healthier lives in new “From Hope to Cures” ads

By Ieva M. Augstums  |    September 6, 2016
For Ed, a longer life meant more time with family, friends and his dog, BearBear. When he was diagnosed with colon cancer, he underwent six weeks of radiation, seven months of chemotherapy and 10...   Read More

ICER puts hard-fought progress in non-small cell lung cancer treatment at risk

By Holly Campbell  |    September 1, 2016
Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell...   Read More

Putting the cost of medicines in context

By Holly Campbell  |    August 4, 2016
Discussions about costs are important. No patient should have to worry about whether they can afford the care they need. At the same time, it is important to look at costs across the health care...   Read More

What they are saying about ICER’s scoping document for non-small cell lung cancer

By Holly Campbell  |    July 11, 2016
The Institute for Clinical and Economic Review (ICER) has set its sights on a new target: life-saving treatments for advanced non-small cell lung cancer (NSCLC). ICER’s latest draft scoping...   Read More

Celebrating diversity in the biopharmaceutical industry

By Andrew Powaleny  |    June 30, 2016
At PhRMA, we often talk about the complexity of developing innovative medicines. Critical to researching new medicines is a workforce that combines sheer brainpower with a level of perseverance...   Read More

America’s biopharmaceutical researchers advance the science of hope in new “From Hope to Cures” ads

By Ieva M. Augstums  |    June 14, 2016
Jen and Yingzi are in the problem-solving business. Every day, they tackle one of the toughest health care problems: cancer. While many others like them across the biopharmaceutical industry work...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates